Greenwood-Goodwin, Midori
Yang, Jiwei
Hassanipour, Mohammad
Larocca, David
Article History
Received: 5 January 2016
Accepted: 29 March 2016
First Online: 25 April 2016
Competing interests
: M.G.-G., M.H. and D.L. are employees of ReCyte Therapeutics, Inc., a subsidiary of BioTime, Inc. and investor in Ascendance Biotechnology, Inc. All aforementioned companies are operating in the field of regenerative medicine, including the commercial development and sale of research and clinical grade cell lines described in this paper. The authors have no additional affiliations or financial involvement with any organization or entity having a financial interest in the content or materials discussed within the manuscript.